Tirzepatide demonstrated non-inferiority to dulaglutide for major adverse cardiovascular events (HR 0.92; 95% CI 0.83-1.02) and reduced cardiovascular death or heart failure events by 38%.
Meta-Analysis (n=25,847)
Does tirzepatide improve multisystem therapeutic outcomes including cardiovascular, heart failure, and metabolic endpoints across diverse patient populations?
Tirzepatide provides comprehensive cardiometabolic protective effects across multiple organ systems, including significant benefits in HFpEF, MASH, and sleep apnea.
Effect estimate: HR 0.92 (95% CI 0.83-1.02)
OBJECTIVES: To comprehensively synthesize and quantify the multi-organ effects of tirzepatide across 10 health domains beyond its primary indications for type 2 diabetes and obesity. METHODS: We searched PubMed, Embase, and CENTRAL through January 2026 for randomized controlled trials (RCTs) of tirzepatide (≥24 weeks) reporting on cardiovascular, heart failure, renal, MASH, obstructive sleep apnea, blood pressure, lipids, quality of life, body composition, or inflammatory outcomes. Data from 17 RCTs (N=25,847) were pooled using random-effects models, with risk of bias assessed via Cochrane RoB 2 and evidence certainty rated using GRADE. RESULTS: Tirzepatide demonstrated non-inferiority to dulaglutide for major adverse cardiovascular events (HR 0.92, 95% CI 0.83-1.02). In HFpEF patients, it reduced cardiovascular death or heart failure events by 38% (HR 0.62, 95% CI 0.41-0.95). Additional benefits included: MASH resolution in 62% of patients (RR 5.33), clinically significant apnea-hypopnea index reduction (21.9 events/hour), systolic blood pressure reduction (5.8 mmHg), triglyceride reduction (19.6%), eGFR preservation (+1.5 mL/min/year), and hsCRP reduction (32.9%). CONCLUSIONS: Tirzepatide provides clinically significant, multi-organ benefits across heart failure, MASH, sleep apnea, blood pressure, lipids, and inflammation. Supported by moderate-to-high certainty evidence, it emerges as a comprehensive cardiometabolic protective agent. However, findings for domains like heart failure and MASH resolution rely on few trials, necessitating cautious interpretation regarding generalizability.
Eisa et al. (Tue,) conducted a meta-analysis in Cardiometabolic conditions (n=25,847). Tirzepatide vs. Dulaglutide was evaluated on Major adverse cardiovascular events (HR 0.92, 95% CI 0.83-1.02). Tirzepatide demonstrated non-inferiority to dulaglutide for major adverse cardiovascular events (HR 0.92; 95% CI 0.83-1.02) and reduced cardiovascular death or heart failure events by 38%.